Clinical Research Treatment Flowchart First Line Resectable First Line Metastatic or unresectable without previous CPI First Line Stage 3 Neoadjuvant Adjuvant Melanoma Trials SWOG 2015 ID: 1040520
Download Presentation The PPT/PDF document "Skin Disease-Oriented Team" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. SkinDisease-Oriented Team Clinical Research Treatment Flowchart
2. First Line, ResectableFirst Line, Metastatic or unresectable without previous CPIFirst Line, Stage 3Neoadjuvant + AdjuvantMelanoma TrialsSWOG 20151cm v 2cm marginCRC: N. ArechigaAccrual: 2/30 UCI 21-226L19IL2 + L19TNFCRC: N. ArechigaAccrual: 1/6EA6194TLR9 agonist+Pembro + Sx vs Pembro + SxCRC: E. Palmer-TorrisonAccrual: 0/6EA 6141(III or IV)Ipi + Nivo + sargramostin vs. Ipi + NivoCRC: B. HuynhAccrual: 4/5UCI 22-101(III or IV)Nivo + Rela IV vs SubQCRC: N. ArechigaAccrual: 3/5Second LineUCI 22-49Low Dose Cyclophosphamide + PembroCRC: N/AAccrual: N/AUCI 22-213E7386 + Pembro +/- Lenvatinib PI: DayyaniCRC: N. ArechigaAccrual: 0/14Pending Activation or SuspendedOpenLow Accrual
3. Melanoma TrialsConsider Broad Phase 1 StudiesUCI 21-38First in Human (FIH), LVGN6051 +/- pembroCRC: E. Palmer-Torrison Accrual: 5/8NRAS mutantUCI 20-169Belvarafenib +/- cobimetinib +/- atezolizumabCRC: E. Palmer-Torrison Accrual: 0/10HER2 + / ERBB2 ampUCI 20-67DF1001 (HER2 NK- engager)PI: ValerinCRC: M. Nguyen Accrual: 18/20UCI 21-247Toripalimab + TAB004CRC: B. HuynhAccrual: 1/6UCI 21-229SGN1 (modified bacteria)CRC: B. HuynhAccrual: 1/6UCI 21-40(Locally Advanced or Metastatic Solid Tumors) DF6002 as a Monotherapy and in Combination w/ nivoValerinCRC: B. HuynhAccrual: 3/6UCI 20-110TAK-981 + Pembro(sumoylation inhibitor)(Tewari)CRC: N. PatelAccrual: 2/5Pending Activation or SuspendedOpenLow Accrual
4. Melanoma TrialsNon-treatment TrialsPending Activation or SuspendedOpenLow AccrualUCI 19-135DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)CRC: Anastasiia R.Accrual: 61/80
5. Pending Activation or SuspendedOpenLow AccrualMerkel Cell Carcinoma TrialsFirst Line, Stage 3Neoadjuvant + AdjuvantEA6174/ STAMP (closed)adjuvant pembrolizumab (I, II)neoadjuvant pembrolizumab (IIIa, IIIb)CRC: N. ArechigaAccrual: 8/13UCI 18-84/ ADAMadjuvant avelumab (III)CRC: N. ArechigaAccrual: 9/12
6. Pending Activation or SuspendedOpenLow AccrualClosedCutaneous Squamous Cell Carcinoma TrialsNo Active SCC specific trials